Gabriele Campi, PhD

Gabriele Campi, PhD, has a diverse work experience in the biotech industry. Gabriele is currently the CEO of ExoLab Italia, a position they have held since 2023. Prior to that, they co-founded and served as the Managing Partner of AurorA-TT, a company focused on technology transfer in the Italian research arena. Gabriele also co-founded and served as a Managing Partner of AurorA Science from 2019 to 2023.

Gabriele has held several board level positions, including a role as a Board Member at InteRNA Technologies BV from 2021 to 2023. Gabriele also held the position of Co-Founder and Project Manager at Altheia Science from 2018 to 2019.

Earlier in their career, Gabriele worked as a Business Development Manager at TTFactor Srl from 2013 to 2015, where they supported researchers and clinicians in evaluating the commercial potentials of their inventions. Gabriele also gained experience as a Senior Associate at NovaSecta Ltd from 2010 to 2012, where they focused on small to mid-sized pharmaceutical and biotech companies.

Gabriele started their career as a Biotech Investment Associate at TTVenture from 2008 to 2010, where they dealt with early-stage investments in drug discovery and diagnostics. Gabriele also worked as a Biotech Investment Analyst at Quantica SGR from 2007 to 2008, focusing on early-stage biotech investments and intellectual property licensing. Gabriele began their career as a Biotech Investment Analyst intern at Nextech Invest Ltd in 2007.

Gabriele Campi, PhD has a diverse education history. From 1992 to 1997, they attended Università degli Studi di Milano, where they earned their Bachelor of Science degree in Immunology - Biology. Gabriele furthered their education at New York University from 2001 to 2006, where they completed their PhD in Immunology. In 2012 to 2013, Gabriele pursued a different field of study and received an Associate's Degree in Audio Engineering and Production from SAE Institute Milan.